Etretinate and visual function: a 1-year follow-up study.
Concern has been expressed in the literature that the drug etretinate may be potentially retinotoxic. Four patients are reported who have received long-term treatment with etretinate and who have undergone detailed evaluation for the development of visual dysfunction over a 1-year period. Despite prolonged treatment and high total doses no evidence of ocular toxicity attributable to the drug was found in any of the patients.
Pitts
J F
JF
Tennent Institute of Ophthalmology, Western Infirmary, Glasgow, U.K.
Mackie
R M
RM
Dutton
G N
GN
McClure
E A
EA
Allan
D
D
D004476:Ectodermal Dysplasia / Q000188:drug therapy; D004890:Erythema / Q000188:drug therapy; D005050:Etretinate / Q000009:adverse effects* / Q000627:therapeutic use; D005500:Follow-Up Studies; D006801:Humans; D011565:Psoriasis / Q000188:drug therapy; D012160:Retina / Q000187:drug effects; D014786:Vision Disorders / Q000139:chemically induced*; D014785:Vision, Ocular / Q000187:drug effects; D014792:Visual Acuity / Q000187:drug effects; D014794:Visual Fields / Q000187:drug effects
D005050:Etretinate